BRPI0112115B8 - compostos moduladores ppar-gamma de quinolinil e benzotiazolil - Google Patents
compostos moduladores ppar-gamma de quinolinil e benzotiazolilInfo
- Publication number
- BRPI0112115B8 BRPI0112115B8 BRPI0112115A BR0112115A BRPI0112115B8 BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8 BR PI0112115 A BRPI0112115 A BR PI0112115A BR 0112115 A BR0112115 A BR 0112115A BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8
- Authority
- BR
- Brazil
- Prior art keywords
- ppar
- benzothiazolyl
- quinolinyl
- compounds
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Quinoline Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21481000P | 2000-06-28 | 2000-06-28 | |
| PCT/US2001/020756 WO2002000633A1 (en) | 2000-06-28 | 2001-06-27 | Quinolinyl and benzothiazolyl ppar-gamma modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0112115A BR0112115A (pt) | 2003-04-29 |
| BRPI0112115B1 BRPI0112115B1 (pt) | 2016-07-26 |
| BRPI0112115B8 true BRPI0112115B8 (pt) | 2021-05-25 |
Family
ID=22800496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0112115A BRPI0112115B8 (pt) | 2000-06-28 | 2001-06-27 | compostos moduladores ppar-gamma de quinolinil e benzotiazolil |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1296967B1 (enExample) |
| JP (1) | JP4515026B2 (enExample) |
| KR (1) | KR100771286B1 (enExample) |
| CN (1) | CN1243741C (enExample) |
| AT (1) | ATE327984T1 (enExample) |
| AU (2) | AU2001271637B2 (enExample) |
| BR (1) | BRPI0112115B8 (enExample) |
| CA (1) | CA2412723C (enExample) |
| CY (1) | CY1105126T1 (enExample) |
| CZ (1) | CZ302982B6 (enExample) |
| DE (1) | DE60120163T2 (enExample) |
| DK (1) | DK1296967T3 (enExample) |
| EA (1) | EA005976B1 (enExample) |
| ES (1) | ES2265435T3 (enExample) |
| HK (1) | HK1052351B (enExample) |
| HU (1) | HUP0301482A3 (enExample) |
| IL (2) | IL153461A0 (enExample) |
| MX (1) | MXPA02012708A (enExample) |
| NO (1) | NO325448B1 (enExample) |
| NZ (1) | NZ523229A (enExample) |
| PL (1) | PL214670B1 (enExample) |
| PT (1) | PT1296967E (enExample) |
| SK (1) | SK288236B6 (enExample) |
| WO (1) | WO2002000633A1 (enExample) |
| ZA (1) | ZA200210283B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| BR0212512A (pt) | 2001-09-14 | 2004-10-26 | Tularik Inc | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| EP2402310A1 (en) | 2002-05-24 | 2012-01-04 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| CA2500492C (en) | 2002-11-18 | 2010-03-16 | Solomon Ungashe | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| RU2005128501A (ru) | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
| AU2004229467B2 (en) * | 2003-04-11 | 2007-01-25 | The University Of Tennessee Research Foundation | Lysophosphatidic acid analogs and inhibition of neointima formation |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US7544702B2 (en) | 2004-08-12 | 2009-06-09 | Amgen Inc. | Bisaryl-sulfonamides |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US7915429B2 (en) | 2006-01-25 | 2011-03-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009525982A (ja) | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| EP1996567B1 (en) * | 2006-02-15 | 2013-09-18 | AbbVie Inc. | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| NZ576197A (en) * | 2006-09-21 | 2011-12-22 | Piramal Life Sciences Ltd | 3 -amino- pyridine derivatives for the treatment of metabolic disorders |
| WO2012162463A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| CN109651208B (zh) * | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US6200995B1 (en) * | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
| JP4295458B2 (ja) * | 1999-06-30 | 2009-07-15 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ活性調節用化合物 |
-
2001
- 2001-06-27 BR BRPI0112115A patent/BRPI0112115B8/pt not_active IP Right Cessation
- 2001-06-27 KR KR1020027017927A patent/KR100771286B1/ko not_active Expired - Lifetime
- 2001-06-27 ES ES01950669T patent/ES2265435T3/es not_active Expired - Lifetime
- 2001-06-27 DK DK01950669T patent/DK1296967T3/da active
- 2001-06-27 WO PCT/US2001/020756 patent/WO2002000633A1/en not_active Ceased
- 2001-06-27 AU AU2001271637A patent/AU2001271637B2/en not_active Expired
- 2001-06-27 PL PL359996A patent/PL214670B1/pl unknown
- 2001-06-27 EP EP01950669A patent/EP1296967B1/en not_active Expired - Lifetime
- 2001-06-27 HK HK03104574.3A patent/HK1052351B/en not_active IP Right Cessation
- 2001-06-27 SK SK1835-2002A patent/SK288236B6/sk not_active IP Right Cessation
- 2001-06-27 MX MXPA02012708A patent/MXPA02012708A/es active IP Right Grant
- 2001-06-27 PT PT01950669T patent/PT1296967E/pt unknown
- 2001-06-27 AU AU7163701A patent/AU7163701A/xx active Pending
- 2001-06-27 DE DE60120163T patent/DE60120163T2/de not_active Expired - Lifetime
- 2001-06-27 JP JP2002505381A patent/JP4515026B2/ja not_active Expired - Lifetime
- 2001-06-27 IL IL15346101A patent/IL153461A0/xx active IP Right Grant
- 2001-06-27 CA CA2412723A patent/CA2412723C/en not_active Expired - Lifetime
- 2001-06-27 HU HU0301482A patent/HUP0301482A3/hu unknown
- 2001-06-27 NZ NZ523229A patent/NZ523229A/en not_active IP Right Cessation
- 2001-06-27 EA EA200300078A patent/EA005976B1/ru not_active IP Right Cessation
- 2001-06-27 AT AT01950669T patent/ATE327984T1/de active
- 2001-06-27 CZ CZ20024197A patent/CZ302982B6/cs not_active IP Right Cessation
- 2001-06-27 CN CNB018120172A patent/CN1243741C/zh not_active Expired - Lifetime
-
2002
- 2002-12-16 IL IL153461A patent/IL153461A/en unknown
- 2002-12-19 ZA ZA2002/10283A patent/ZA200210283B/en unknown
- 2002-12-20 NO NO20026156A patent/NO325448B1/no not_active IP Right Cessation
-
2006
- 2006-08-07 CY CY20061101099T patent/CY1105126T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0112115B8 (pt) | compostos moduladores ppar-gamma de quinolinil e benzotiazolil | |
| DE69800730D1 (de) | Formular das unerlaubtes lesen erkennen lässt, zur sicheren übermittlung von informationen | |
| BR9714242A (pt) | Hidrosipropilcelulose metilada e produtos sensìveis `a temperatura fabricados a partir da mesma | |
| BR0011446A (pt) | Método de inibição da agregação de proteìna amilóide e formação de imagem de depósitos de amilóide usando derivados de isoindolina | |
| HUP9901132A2 (hu) | 2-Alkilpirrolidinek | |
| BR0315450A (pt) | Circuito eletrônico à prova de violação para implantação de um dispositivo, dispositivo implementado com um circuito eletrônico à proca de violação, e, métodos de gerenciamento de dados de segurança para um dispositivo, para manter segurança de dados em relação a comunicação de rede entre um dispositivo de rede e um parceiro de comunicação externa, e para marcar conteúdo digital produzido por um dispositivo de produção de conteúdo. | |
| BR0112033A (pt) | Método para tratamento de substratos minerais | |
| BR9806752A (pt) | Ftalazinonas. | |
| BR9510420A (pt) | Azetidin-2-onas substituìdas para o tratamento de aterosclerose | |
| NO20054989D0 (no) | 1,2,4-substituerte 1,2,3,4-tetrahydro og 1,2,dihydro-quinolin og 1,2,3,4-tetrahydro-quinoksalinderivater som CETP inhibitorer for behandlingen av aterosklerose og fedme | |
| ATE472992T1 (de) | Stabilisierung von körperpflegemittel und haushaltsmitteln | |
| NZ585829A (en) | Hydrolysis resistant organomodified trisiloxane ionic surfactant compositions and aqueous emulsion thereof | |
| FI861995A0 (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4-benzoyl-1-piperidinyl)-1 -fenylalkanolderivat. | |
| DE602004009357D1 (de) | Netzwerkzonen | |
| TR200201613T2 (tr) | Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler | |
| DE60007939D1 (de) | Wäschewaschmaschine | |
| ES2121440T3 (es) | Instalacion de plasma. | |
| ATE204867T1 (de) | Alkylendiamin-derivate als arzneimittel zur behandlung von geschwüren und hemmung von helicobacter pylori | |
| FI972850A0 (fi) | Optisesti vaalennettujen muovien käyttö paperin päällystyslietteiden vaalentamiseksi optisesti ja tällä tavoin optisesti vaalennettuja paperin päällystyslietteitä | |
| BR0012072A (pt) | Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário | |
| BR0009856A (pt) | Sìntese de 3-amino-3-aril propanoatos | |
| BR0308685A (pt) | Enlace de bloqueio de frequência e fase direcionado por dados para decodificar um sinal modulado por desvio de qam tendo um piloto | |
| BR9912000A (pt) | Uso de derivados de tetraidropiridina (ou 4-hipropiperidina)- butilazóis na preparação de medicamento para tratamento de dor | |
| DK293890D0 (da) | 3-oe2,(4-arylpiperazin1-yl)-ethoxylaap-cymen, derivater deraf, som er ortho-, meta- og paramonosubstituerede eller -disubstituerede paa phenylringen, fremgangsmaade til fremstilling af saadanne derivater samt laegemidler, hvori forbindelserne er til stede som det aktive middel | |
| TR200000652T2 (tr) | Dokümanlar için eğimli optik güvenlik elemanlarının yapılandırılması ve bu güvenlik elemanlarının kontrolü için geliştirilen bir tertibat ve bu güvenlik elemanları ve tertibatlarının uygulanması işlemi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 22A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2728 DE 18/04/2023 POR TER SIDO INDEVIDA. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 27/06/2021 |